Anne C. Fleischer, Global VP of Consumer Engagement & New Business Models at Novo Nordisk, and Henrijette Richter, Managing Partner at Sofinnova Partners, join Andreas Munk Holm on stage at the EUCVC Summit 2025 to explore how corporates and VCs are shaping the next wave of health innovation.
From personalized treatments powered by AI, to the crucial role of data rights and trust in scaling digital health, Anne and Henrijette share hard-won insights on how pharma and venture can collaborate without killing speed or innovation.
They discuss the “impatience economy,” where patients increasingly demand fast, personalized solutions, and why collaboration across startups, corporates, and investors is essential to turn science into scalable business models.
🎧 Here’s what’s covered
00:00 The next wave of health innovation — AI, deep tech, and strategic investment.
01:00 Beyond the pill — Novo Nordisk’s vision for personalized, AI-driven patient care.
03:00 Investor lens — what separates fundable AI health companies from “science projects.”
04:00 Data rights & distribution — why exclusivity and integration pathways are critical.
05:00 Corporate–startup collaboration — Novo Nordisk’s partner platform for scaling innovation.
06:00 Scaling globally from day one — why diversified data and pharma channels matter.
07:00 The “translator role” — people who speak both startup and corporate languages.
08:00 The impatience economy — consumerization of health and the risks of losing trust.
09:00 Looking ahead — specificity for patients as the next frontier in health innovation.
You can listen to the full session on Apple Podcasts and Spotify. 🎧
✍️ Show Notes
Beyond the Pill
Novo Nordisk pairs GLP-1 treatments with AI-driven personalization.
Patient behavior, preferences, and risk profiles guide tailored interventions.
Investor Perspective (Sofinnova Partners)
Fundable AI health startups must demonstrate:
Clear demand and fast path to revenue.
Strong data rights and reusability.
Integration into existing distribution channels.
Collaboration at Scale
Novo Nordisk’s partner platform connects startups’ APIs and SDKs to millions of patients.
Corporates excel at scaling; startups excel at innovating.
Successful collaboration requires translators who understand both worlds.
Consumerization & Trust
Patients are increasingly willing to bypass regulation (“impatience economy”).
Corporates must safeguard trust while learning from consumer tech’s UX playbook.
Looking Forward
Health innovation will hinge on specificity for patients — precise, personalized, scalable care.
💡 One-liner takeaway:
AI and digital health will only scale if corporates, startups, and VCs strike the right balance between personalization, data rights, and patient trust.
